MDT - Medtronic plc
| Previous Close | 101.34 |
| Open | 102.08 |
| Bid | 101.28 x 800 |
| Ask | 103.99 x 800 |
| Day's Range | 100.79 - 102.74 |
| 52 Week Range | 81.66 - 102.74 |
| Volume | 4,879,476 |
| Avg. Volume | 5,007,073 |
| Market Cap | 135.189B |
| Beta (3Y Monthly) | 0.53 |
| PE Ratio (TTM) | 29.56 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.16 (2.13%) |
| Ex-Dividend Date | 2019-07-05 |
| 1y Target Est | N/A |
- Yahoo Finance Video•3 days ago
Congress set to vote on repeal of 'Cadillac tax'
Yahoo Finance’s Adam Shapiro, Julie Hyman, Scott Gamm, Anjalee Khemlani, and Kristin Myers discuss.
- Zacks•2 days ago
Will USTR's 25% Tariff Exemption Spell Relief for MedTech?
In the wake of the U.S. tariff and Chinese retaliation, the MedTech industry players (with production houses in China) are facing huge bottom line pressure.
- American City Business Journals•2 days ago
Medtronic veteran's diabetes-care startup raises $6 million
Lonny Stormo left Medtronic four years ago to begin work on a new medical device he believes could change the way diabetics live. A 30-year veteran of the medical-device giant and a diabetic himself, Stormo saw an opportunity to modernize the technology used to monitor blood-glucose levels. "We're managing diabetes the same way we've managed it for 20 years," Stormo said.
- Zacks•3 days ago
US-India Trade Tensions Rise: 3 Stocks in the Line of Fire
As India moves toward self-sufficiency, U.S. MedTech bigwigs fret over possible losses.
- Reuters•4 days ago
Abbott to hike production of lower-cost glucose monitors as diabetes soars
Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters. Abbott executives said the increase in manufacturing capacity will begin in the second half of this year and make room for the expected U.S. launch of the FreeStyle Libre 2. Abbott's plans for Libre, its fastest-growing diabetes product, used by 1.5 million people worldwide, will be in focus when the company reports quarterly earnings on Wednesday.
- Reuters•4 days ago
FOCUS- Abbott to hike production of lower-cost glucose monitors as diabetes soars
Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters. Abbott executives said the increase in manufacturing capacity will begin in the second half of this year and make room for the expected U.S. launch of the FreeStyle Libre 2. Abbott's plans for Libre, its fastest-growing diabetes product, used by 1.5 million people worldwide, will be in focus when the company reports quarterly earnings on Wednesday.
- Zacks•8 days ago
Tap AI-Powered Medical Device Stocks as FDA Bolsters SaMD
The whole MedTech community finds a reason to cheer over with the FDA's recent proposal for Software as a Medical Device.
- Motley Fool•10 days ago
The 10 Biggest Healthcare Stocks
How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.
- Zacks•10 days ago
Medtronic Releases Positive Results of LATERAL Clinical Trial
Positive outcomes prove to be a major breakthrough for Medtronic (MDT) in the growing field of ventricular assist devices.
- Markit•11 days ago
See what the IHS Markit Score report has to say about Medtronic PLC.
Medtronic PLC NYSE:MDTView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MDT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MDT. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $4.80 billion over the last one-month into ETFs that hold MDT are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- American City Business Journals•17 days ago
Analysts bullish on Boston Scientific's plans for 75 new products by 2022
Boston Scientific CEO Michael Mahoney laid out the long-term strategy for the company late last week, including a plan to launch 75 new cardiac valve, brain stimulation and other products by 2022.
- Zacks•18 days ago
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Medtronic (MDT) closed at $98.05, marking a -0.05% move from the previous day.
- Zacks•18 days ago
Medtronic's Titan Spine Buyout to Boost Spine Surgery Range
Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.
- Bloomberg•18 days ago
Happy Days for Europe's Giant Bond Sellers
(Bloomberg Opinion) -- Sellers of euro-denominated corporate bonds had their best fund-raising month for three years in June, topping off their best six months since 2012. Some 210 billion euros ($238 billion) in new company debt was snaffled up by investors between January and June, 21% higher than the same period last year.Conditions are rarely better than this for company borrowers as benchmark sovereign bond yields keep falling and credit spreads (the difference between the interest rate on corporate bonds and the yields on those sovereign benchmarks) tighten. And there’s more good news on the horizon possibly, with the European Central Bank thinking about restarting its corporate bond-buying program to help reboot the euro zone’s floundering economy. Goldman Sachs Group Inc. is one of several banks to forecast a return of the ECB to the company credit market.It’s been a frenzy of issuance in 2019, with the consumer goods giants dominating at more than 40% of the total. So-called “Reverse Yankees,” where U.S. companies issue euro-denominated bonds, have featured prominently as American multinationals take advantage of record low interest rates to fund their euro-area operations. Coca-Cola Co., International Business Machines Corp. and Altria Group Inc. all did substantial deals, with nearly 50 billion euros raised this year from U.S entities. The big issuer was Medtronic Plc, a medical products supplier, which came to the market twice with jumbo deals for a total of 12 billion euros.One other statistic stands out at the turn of Europe’s corporate bond year: Nearly half of the issuance has been in maturities of longer than 10 years. As I’ve written regularly, there’s a desperate hunt for yield and investors prefer to buy long-term debt than settle for negative returns.No wonder there’s little sign of the momentum stopping; July is looking very healthy already with eight company issuers announcing new deals on Monday.The chance of the ECB piling in again merely adds to the sense of expectation. Between June 2016 and December 2018 the euro zone’s central bank amassed 178 billion euros of investment grade euro-denominated corporates (although it avoided buying bank paper). The splurge was long-anticipated and credit spreads tightened in expectation of its arrival. A restart to the program – or even the hope of its return – could trigger a similar tightening this time around. If Goldman’s call is correct, that might happen as early as September. This would suggest a balmy summer indeed for credit spreads.To contact the author of this story: Marcus Ashworth at mashworth4@bloomberg.netTo contact the editor responsible for this story: James Boxell at jboxell@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Marcus Ashworth is a Bloomberg Opinion columnist covering European markets. He spent three decades in the banking industry, most recently as chief markets strategist at Haitong Securities in London.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
- Insider Monkey•20 days ago
How Adobe Inc and Other Hedge Fund Favorites Performed in Q2
Insider Monkey tracks hedge funds, billionaires, and prominent value investors for a very simple reason: their consensus picks generally outperform the market. We aren’t the only research shop broadcasting this fact using a bullhorn. Here is what strategist Ben Snider said in Goldman Sachs’ periodic hedge fund report: “Despite the strong track record of popular […]
- American City Business Journals•22 days ago
Direct flights between MSP and Dublin start Monday
Minneapolis-St. Paul International Airport is bringing in a veteran of the high-stepping “Riverdance” show to celebrate the July 1 start of direct service between MSP and Dublin.
- Yahoo Finance•22 days ago
Companies to Watch: Goldman slashes rate, hacker warning from Medtronic, Mattel issues recall
Goldman Sachs, Medtronic, Mattel, Facebook, Google and SpaceX are the companies to watch.
- American City Business Journals•22 days ago
Medtronic, FDA warn of hacking risk to older insulin pumps
Some insulin pumps made by med-tech giant Medtronic are vulnerable to cyberattacks that could let a hacker make dangerous changes to a patient's insulin levels, according to alerts from the company and federal regulators.
- MoneyShow•22 days ago
Medtronic- Pacemakers to Surgical Robots
Medtronic (MDT) was founded in Minneapolis in 1949 as a medical equipment repair company. It is now the world's largest medical device company, headquartered for tax reasons in Dublin, explains Adam Mayers, editor of Adam Mayers Investing.
- Investor's Business Daily•23 days ago
Why This Medtech Stock Could Top Its Own Bullish 3-Year Outlook
Boston Scientific will likely top its own three-year guidance for a 6%-9% compound annual growth rate, analysts said Thursday as the medical technology company expands its heart devices.
- Investor's Business Daily•23 days ago
Medtronic Warns Thousands Of Insulin Pumps Could Be Open To Hackers
Medtronic, the Food and Drug Administration and Homeland Security warned Thursday that potentially thousands of older model Medtronic insulin pumps are susceptible to hackers.
- Reuters•23 days ago
FDA warns of cybersecurity risk to certain Medtronic insulin pumps
"An unauthorized person with special technical skills and equipment could potentially connect wirelessly to a nearby insulin pump to change settings and control insulin delivery," Medtronic said. Medtronic has identified 4,000 patients who are potentially using insulin pumps that are vulnerable to this issue, the agency said.
- Zacks•24 days ago
Medtronic (MDT) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Medtronic (MDT) closed at $97.21, marking a -1.71% move from the previous day.
- Benzinga•25 days ago
Morgan Stanley: Medtronic's $4B Financing Could Be 10-Cent EPS Tailwind
Medtronic PLC (NYSE: MDT )’s announcement that it is commencing an offer for more than $4 billion in debt securities should help the company manage its tax headwind, according to Morgan Stanley. The Analyst ...
